Maturity-Onset Diabetes of the Young (MODY): Genetic and Clinical Characteristics

2002 ◽  
Vol 57 (1) ◽  
pp. 29-33 ◽  
Author(s):  
Gilberto Velho ◽  
Jean-Jacques Robert
2020 ◽  
Vol 9 (5) ◽  
pp. 471-478
Author(s):  
Yuan Zhou ◽  
ShengNan Wang ◽  
Jing Wu ◽  
JianJun Dong ◽  
Lin Liao

Aims Heterozygous inactivating mutations in the GCK gene cause the familial, mild fasting hyperglycaemia named MODY2. Many patients with MODY2 in Asia have delayed timely treatment because they did not receive the correct diagnosis. This study aims to analyze the clinical characteristics and GCK mutations in Asian MODY2. Methods We have collected 110 Asian patients with MODY2 from the PubMed, Embase, Medline, Web of Science, CNKI, and Wanfang with the following search terms: ‘maturity-onset diabetes of the young’ OR ‘MODY’ OR ‘maturity-onset diabetes of the young type 2’ OR ‘MODY2’ OR ‘GCK-DM’ OR ‘GCK-MODY’. Both mutations of GCK and clinical characteristics of MODY2 were analyzed. Results There were 96 different mutations that occurred in coding regions and non-coding regions. Exon 5 and 7 were the most common location in coding regions and missense was the primary mutation type. The proportion of probands younger than 25 was 81.8%, and 81.4% of the probands had family history of hyperglycaemia. Ninety percent and 93% of Asian MODY2 probands exhibited mild elevation in FPG (5.4–8.3 mmol/L) and HbA1c (5.6–7.6%), respectively. Conclusions In most Asian patients, MODY2 occurred due to GCK mutation in coding regions, and exon 5 and 7 were the most common locations. FPG, HbA1c, and familial diabetes were important reference indicators for diagnosing MODY2. Altogether, the study indicates that for the young onset of diabetes with mild elevated blood glucose and HbA1c and family history of hyperglycaemia, molecular genetic testing is suggested in order to differentiate MODY2 from other types of diabetes earlier.


2004 ◽  
Vol 13 (4) ◽  
pp. 422-427 ◽  
Author(s):  
Jian Yu Xu ◽  
Qing Hong Dan ◽  
Vivian Chan ◽  
Nelson M S Wat ◽  
Sidney Tam ◽  
...  

2011 ◽  
Vol 96 (8) ◽  
pp. E1346-E1351 ◽  
Author(s):  
Christine Bellanné-Chantelot ◽  
David Joseph Lévy ◽  
Claire Carette ◽  
Cécile Saint-Martin ◽  
Jean-Pierre Riveline ◽  
...  

2021 ◽  
Author(s):  
Rong Long ◽  
Chen-Xi Yu ◽  
Hui-Jun Yang ◽  
Tai-Cheng Zhou ◽  
Lei Yang ◽  
...  

Abstract Background: Due to the rarity, the type 3 of maturity-onset diabetes of the young (MODY3) has not been explored comprehensively. The study aimed to describe and analyze the molecular and clinical characteristics of MODY3, which could help physicians understand the subtype of diabetes and increase the diagnosis rates in the future.Methods: Ten unrelated patients with suspected maturity-onset diabetes of the young (MODY) were included in the study based on information on family history and onset age. Sanger sequencing was used to identify cases with mutations in the hepatic nuclear factor 1A gene (HNF-1A). Results: Five patients were identified with MODY3, three cases (60%) with p.I27L mutation, one case (20%) with p.S487N mutation, and one case (20%) with p.G574S mutation. The average onset age was (23.00±3.00) years and the average age of diagnosis was (28.67±9.29) years. Most patients had typical clinical symptoms (polydipsia, polyuria, polyphagia, and weight loss). The main complications included diabetic ketoacidosis (DKA, 3/5,60%), diabetic macroangiopathy (2/5,40%), diabetic peripheral neuropathy (DPN,3/5,60%), diabetic nephropathy (DN,1/5,20%) and diabetic retinopathy (DR,1/5,20%). Four patients (80%) had fatty liver. The average body mass index (BMI) (26.39±4.67) kg/㎡, triglyceride (TG 2.95±1.43 mmol/L) and low-density lipoprotein (LDL-C 3.37±0.65 mmol/L) were beyond normal value. The glycosylated hemoglobin A1c (HbA1c 12.45±4.60 %), fasting plasma glucose (FPG 10.10±3.57 mmol/L) and postprandial plasma glucose (PPG 21.88±2.53 mmol/L) also increased dramatically. In addition, islet function examination revealed impaired secretion and slightly poor reserve function, which was similar to the changes inT2DM. All five patients used insulin, three (60%) also using antidiabetic drugs which did not include sulfonylureas.Conclusions: In brief, five patients were identified with MODY3. The mutation site could influence the onset age, the islet function and the incidence of complications. The age at diagnosis was 4.2 years later than the onset age. The control of diabetes was poor due to the inappropriate treatment. It is vital to make an early diagnosis and provide appropriate treatment for MODY3 patients.


2017 ◽  
Author(s):  
Ana Amado ◽  
Raquel Almeida ◽  
Andre Carvalho ◽  
Claudia Amaral ◽  
Claudia Freitas ◽  
...  

2006 ◽  
Vol 74 (1) ◽  
pp. 75-81 ◽  
Author(s):  
Jin Soon Hwang ◽  
Choong Ho Shin ◽  
Sei Won Yang ◽  
Sung young Jung ◽  
Nam Huh

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Xiuzhen Li ◽  
Tzer Hwu Ting ◽  
Huiying Sheng ◽  
Cui Li Liang ◽  
Yongxian Shao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document